View Financial HealthBioGaia 配当と自社株買い配当金 基準チェック /36BioGaia配当を支払う会社であり、現在の利回りは3.39%で、収益によって十分にカバーされています。主要情報3.4%配当利回り0%バイバック利回り総株主利回り3.4%将来の配当利回り4.2%配当成長12.6%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向50%最近の配当と自社株買いの更新お知らせ • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).お知らせ • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.お知らせ • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.お知らせ • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).お知らせ • Feb 07+ 1 more updateBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).すべての更新を表示Recent updatesお知らせ • Feb 13BioGaia AB (publ), Annual General Meeting, May 07, 2026BioGaia AB (publ), Annual General Meeting, May 07, 2026.お知らせ • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).お知らせ • Oct 22+ 2 more updatesBioGaia AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026BioGaia AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 12, 2026お知らせ • Oct 13BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025お知らせ • Aug 22BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the BoardAt an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman.お知らせ • Jul 25Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025.お知らせ • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.お知らせ • Mar 21Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B)Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion). After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction.お知らせ • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.お知らせ • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).お知らせ • Dec 06BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTIONBioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.お知らせ • Oct 22BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025お知らせ • Jul 23BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025お知らせ • Feb 07+ 1 more updateBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).お知らせ • Oct 22+ 1 more updateBioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024BioGaia AB (publ) announced that they will report first half, 2024 results on Jul 07, 2024お知らせ • Oct 19+ 1 more updateBioGaia AB (publ), Annual General Meeting, Apr 26, 2024BioGaia AB (publ), Annual General Meeting, Apr 26, 2024.お知らせ • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.お知らせ • Sep 26Biogaia AB (Publ) Appoints Theresa Agnew as CEOBioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.お知らせ • Sep 02BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in SwedenBioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199.お知らせ • Aug 03BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.お知らせ • Jul 06BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adultsA randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections.決済の安定と成長配当データの取得安定した配当: BGLA.Fの配当金支払いは、過去10年間 変動性 が高かった。増加する配当: BGLA.Fの配当金は過去10年間にわたって増加しています。配当利回り対市場BioGaia 配当利回り対市場BGLA.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BGLA.F)3.4%市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Biotechs)2.4%アナリスト予想 (BGLA.F) (最長3年)4.2%注目すべき配当: BGLA.Fの配当金 ( 3.39% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) よりも高くなっています。高配当: BGLA.Fの配当金 ( 3.39% ) はUS市場の配当金支払者の上位 25% ( 4.25% ) と比較すると低いです。株主への利益配当収益カバレッジ: BGLA.Fの 配当性向 ( 49.9% ) はかなり低いため、配当金の支払いは利益によって十分にカバーされます。株主配当金キャッシュフローカバレッジ: BGLA.Fは高い 現金配当性向 ( 133.6% ) のため、配当金の支払いはキャッシュフローで十分にカバーされていません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/07 21:32終値2026/01/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioGaia AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Christopher UhdeABG Sundal Collier SponsoredMattias HäggblomDanske BankKristofer Liljeberg-SvenssonDNB Carnegie
お知らせ • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).
お知らせ • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.
お知らせ • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.
お知らせ • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).
お知らせ • Feb 07+ 1 more updateBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).
お知らせ • Feb 13BioGaia AB (publ), Annual General Meeting, May 07, 2026BioGaia AB (publ), Annual General Meeting, May 07, 2026.
お知らせ • Feb 12+ 1 more updateBiogaia AB (Publ) Proposes Extra DividendBioGaia AB (publ) announced that the board will propose at the upcoming Annual General Meeting on 7 May 2026 an extra dividend of SEK 2.36 per share (4.95 per share).
お知らせ • Oct 22+ 2 more updatesBioGaia AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026BioGaia AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 12, 2026
お知らせ • Oct 13BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025
お知らせ • Aug 22BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the BoardAt an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman.
お知らせ • Jul 25Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025.
お知らせ • May 08+ 1 more updateBioGaia AB (publ) Approves Extra DividendBioGaia AB (publ) announced that at its AGM held on 7 May 2025, the shareholders approved an extra dividend of SEK 4.95 per share.
お知らせ • Mar 21Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B)Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion). After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction.
お知らせ • Feb 26BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025.
お知らせ • Feb 13+ 2 more updatesBioGaia AB (publ) Proposes Extra DividendThe Board of BioGaia AB (publ) proposed that the upcoming Annual General Meeting on 7 May 2025 approves an extra dividend of SEK 4.95 (5.00) per share resulting in a total dividend of SEK 6.90 (6.90) per share, corresponding to SEK 698.0 million (696.8).
お知らせ • Dec 06BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTIONBioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation.
お知らせ • Oct 22BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025
お知らせ • Jul 23BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025
お知らせ • Feb 07+ 1 more updateBiogaia AB (Publ) Proposes an Extra DividendBioGaia AB (publ) proposed an extra dividend of SEK 5.00 (1.45) per share resulting in a total dividend of SEK 6.90 (2.90) per share, corresponding to SEK 696.8 million (292.8 million).
お知らせ • Oct 22+ 1 more updateBioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024BioGaia AB (publ) announced that they will report first half, 2024 results on Jul 07, 2024
お知らせ • Oct 19+ 1 more updateBioGaia AB (publ), Annual General Meeting, Apr 26, 2024BioGaia AB (publ), Annual General Meeting, Apr 26, 2024.
お知らせ • Oct 17Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%.
お知らせ • Sep 26Biogaia AB (Publ) Appoints Theresa Agnew as CEOBioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
お知らせ • Sep 02BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in SwedenBioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199.
お知らせ • Aug 03BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements.
お知らせ • Jul 06BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adultsA randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections.